Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoids

• Published in: Cancer cell international 2021-10, Vol.21 (1), p.1-519, Article 519
• Main Authors: Wang, Zhiwei, Guo, Yinghao, Jin, Yun, Zhang, Xiaoxiao, Geng, Hao, Xie, Guangyuan, Ye, Dan, Yu, Yuanquan, Liu, Daren, Zhou, Donger, Li, Baizhou, Luo, Yan, Peng, Shuyou, Li, Jiangtao
• Format: Article
• Language: English
• Subjects: 5-Fluorouracil; Adenocarcinoma; Biliary tract; Cancer therapies; Chemotherapy; Cholangiocarcinoma; Cisplatin; Digestive system; Drug screening; Extrahepatic biliary tract carcinoma; Gallbladder cancer; Gemcitabine; Genetic profiles; Growth factors; Growth rate; Medical prognosis; Microenvironments; Morphology; Organoids; Paclitaxel; Pathological staining; Patients; Physiology; Primary Research; Single-nucleotide polymorphism
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/s12935-021-02219-w

Background Patient-derived organoids (PDO) have been proposed as a novel in vitro method of drug screening for different types of cancer. However, to date, extrahepatic biliary tract carcinoma (eBTC) PDOs have not yet been fully established. Methods We collected six samples of gallbladder carcinoma (GBC) and one sample of extrahepatic cholangiocarcinoma (eCCA) from seven patients to attempt to establish eBTC PDOs for drug screening. We successfully established five GBC and one eCCA PDOs. Histological staining was used to compare structural features between the original tissues and cancer PDOs. Whole exome sequencing (WES) was performed to analyze the genetic profiles of original tissues and cancer PDOs. Drug screening, including gemcitabine, 5-fluorouracil, cisplatin, paclitaxel, infigratinib, and ivosidenib, was measured and verified by clinical effects in certain cases. Results Different PDOs exhibited diverse growth rates during in vitro culture. Hematoxylin and eosin staining demonstrated that the structures of most cancer PDOs retained the original structures of adenocarcinoma. Immunohistological and periodic acid-schiff staining revealed that marker expression in cancer PDOs was similar to that of the original specimens. Genetic profiles from the four original specimens, as well as paired cancer PDOs, were analyzed using whole exome sequencing. Three of the four PDOs exhibited a high degree of similarity when compared to the original specimens, except for GBC2 PDO, which only had a concordance of 74% in the proportion of single nucleotide polymorphisms in the coding sequence. In general, gemcitabine was found to be the most efficient drug for eBTC treatment, as it showed moderate or significant inhibitory impact on cancer growth. Results from drug screening were confirmed to a certain extent by three clinical cases. Conclusions Our study successfully established a series of eBTC PDOs, which contributed to the field of eBTC PDOs. Additional enhancements should be explored to improve the growth rate of PDOs and to preserve their immune microenvironment.